PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35648093.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0541.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1. See related article by Peper-Gabriel et al., p. 3387.
Medical subject headings
- B7-H1 Antigen
- Neoplasms